Cyclic nucleotide-gated channel alpha 3

AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials

Retrieved on:

Wednesday, June 23, 2021

Vision, Branches of biology, Ion channels, Nervous system, Channelopathies, Cyclic nucleotide gated channel beta 3, Achromatopsia, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa, Retinitis, Applied Genetic Technologies Corporation

AGTC management will host a conference call and webcast with accompanying slides beginning at 8:00 AM Eastern Time on the same date to review the ACHM CNGB3 and CNGA3 data and provide an update on the trials.

Key Points:

AGTC management will host a conference call and webcast with accompanying slides beginning at 8:00 AM Eastern Time on the same date to review the ACHM CNGB3 and CNGA3 data and provide an update on the trials.
The live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations .
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).
AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC to Present at American Optometric Association’s Optometry’s Meeting

Retrieved on:

Tuesday, June 22, 2021

Branches of biology, Vision, Biology, Channelopathies, Ion channels, Achromatopsia, Agnosía, Visual perception, Visual system, Applied Genetic Technologies Corporation, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3

Dr. Lin also will also lead three continuing education courses related to gene therapy and IRDs.

Key Points:

Dr. Lin also will also lead three continuing education courses related to gene therapy and IRDs.
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).
AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC Expands Leadership Team with Appointment of Key Regulatory Leader

Retrieved on:

Wednesday, May 26, 2021

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.

Key Points:

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).
AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 17, 2021

Retrieved on:

Tuesday, May 11, 2021

AGTC management will host a conference call beginning at 4:30 PM Eastern Time on the same date to review results and provide a corporate update.\nTo access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US).

Key Points:

AGTC management will host a conference call beginning at 4:30 PM Eastern Time on the same date to review results and provide a corporate update.\nTo access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US).
A live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations .
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).
AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss XLRP Full 12-Month Data from Highest Dose Groups and 24-Month Data from a Subset of Group 4 Patients of its Ongoing Phase 1/2 Clinical Trial

Retrieved on:

Wednesday, May 5, 2021

To access the call, dial 866-269-4262 (US) or 323-347-3278 (outside of the US) referencing conference ID# 9770776.

Key Points:

To access the call, dial 866-269-4262 (US) or 323-347-3278 (outside of the US) referencing conference ID# 9770776.
AGTC\xe2\x80\x99s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).
AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting

Retrieved on:

Tuesday, May 4, 2021

AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs.

Key Points:

AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).
Its preclinical programs build on the Company\xe2\x80\x99s industry leading AAV manufacturing technology and scientific expertise.
AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials

Retrieved on:

Monday, May 3, 2021

Vision, Branches of biology, Nervous system, Channelopathies, Ion channels, Achromatopsia, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa, Clinical trial

Dr. Yang also will review efficacy data from centrally dosed patients.

Key Points:

Dr. Yang also will review efficacy data from centrally dosed patients.
At six months, the data showed increased mean sensitivity relative to baseline as assessed by microperimetry, and these results were durable through month 12.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).
AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC Announces Data to be Presented from the Ongoing XLRP and Achromatopsia Clinical Trials at the ARVO 2021 Virtual Annual Meeting

Retrieved on:

Thursday, April 29, 2021

Vision, Nervous system, Sensory systems, Channelopathies, Ion channels, Visual system, Achromatopsia, Visual perception, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa, Retinitis

AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs.

Key Points:

AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs.
AGTC\xe2\x80\x99s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).
AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC Announces Departure of Chief Scientific Officer

Retrieved on:

Monday, April 26, 2021

Vision, Branches of biology, Nervous system, Ion channels, Channelopathies, Achromatopsia, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa, Translational research, Vision, Branches of biology, Nervous system, Ion channels, Channelopathies, Achromatopsia, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa, Translational research, Vision, Branches of biology, Nervous system, Ion channels, Channelopathies, Achromatopsia, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa, Translational research, Vision, Branches of biology, Nervous system, Ion channels, Channelopathies, Achromatopsia, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa, Translational research

Shearman has had a successful tenure leading AGTC\xe2\x80\x99s product candidate selection process, pre-clinical and translational research and long-term research and development planning,\xe2\x80\x9d said Sue Washer, President and CEO of AGTC.

Key Points:

Shearman has had a successful tenure leading AGTC\xe2\x80\x99s product candidate selection process, pre-clinical and translational research and long-term research and development planning,\xe2\x80\x9d said Sue Washer, President and CEO of AGTC.
\xe2\x80\x9cThe company has progressed to an exciting stage with promising clinical data emerging and a strong pipeline in place.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).
AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC Announces New Initiatives To Enhance The Patient Journey In Its XLRP Trials

Retrieved on:

Thursday, March 25, 2021

Vision, Branches of biology, Ion channels, Nervous system, Channelopathies, Achromatopsia, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Clinical trial, Retinitis pigmentosa

In addition to upgrading the AGTC website, AGTC also has developed a website that is dedicated to XLRP information and can be accessed at www.scenictrials.com .

Key Points:

In addition to upgrading the AGTC website, AGTC also has developed a website that is dedicated to XLRP information and can be accessed at www.scenictrials.com .
To assist those who want to learn more about AGTCs XLRP clinical trials, AGTC partnered with Serva Health, a nurse-staffed patient engagement center, to assist them in navigating the clinical trial experience.
This partnership provides access to nurses who can answer questions to help potential participants better understand the XLRP clinical trials.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).